Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy

Timothy M. Pawlik, Merrick I. Ross, Marcella M. Johnson, Christopher W. Schacherer, Dana M. McClain, Paul F. Mansfield, Jeffrey E. Lee, Janice N. Cormier, Jeffrey E. Gershenwald

Research output: Contribution to journalArticle

Abstract

Background: In-transit recurrence is a unique and uncommon pattern of treatment failure in patients with melanoma. Little information exists concerning the incidence, predictors, and natural history of in-transit disease since the introduction of sentinel lymph node biopsy (SLNB). Methods: Between 1991 and 2001, 1395 patients with primary melanoma underwent SLNB. Univariate and multivariate logistic regression analyses were performed to examine the association among known clinicopathologic factors, in-transit recurrence, and distant metastatic failure after the development of in-transit disease. Results: With a median follow-up of 3.9 years, 241 patients (17.3%) experienced disease recurrence, including 91 (6.6%) who developed in-transit recurrence. Independent predictors of in-transit recurrence included age >50 years, a lower extremity location of the primary tumor, Breslow depth, ulceration, and sentinel lymph node (SLN) status. Of the 69 patients who presented with in-transit disease as the sole site of first recurrence, 39 developed distant disease. By univariate analysis, predictors of distant failure among patients with in-transit disease included SLN status, largest metastatic focus in the SLN >2.5 mm2, subcutaneous location of in-transit disease, in-transit tumor size ≥ 2 cm, and a disease-free interval before in-transit recurrence of

Original languageEnglish (US)
Pages (from-to)587-596
Number of pages10
JournalAnnals of Surgical Oncology
Volume12
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Lymph Node Excision
Natural History
Melanoma
Recurrence
Sentinel Lymph Node Biopsy
cyhalothrin
Treatment Failure
Lower Extremity
Neoplasms
Logistic Models
Regression Analysis
Incidence
Sentinel Lymph Node

Keywords

  • In transit
  • Lymph node
  • Melanoma
  • Recurrence
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Pawlik, T. M., Ross, M. I., Johnson, M. M., Schacherer, C. W., McClain, D. M., Mansfield, P. F., ... Gershenwald, J. E. (2005). Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Annals of Surgical Oncology, 12(8), 587-596. https://doi.org/10.1245/ASO.2005.05.025

Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. / Pawlik, Timothy M.; Ross, Merrick I.; Johnson, Marcella M.; Schacherer, Christopher W.; McClain, Dana M.; Mansfield, Paul F.; Lee, Jeffrey E.; Cormier, Janice N.; Gershenwald, Jeffrey E.

In: Annals of Surgical Oncology, Vol. 12, No. 8, 08.2005, p. 587-596.

Research output: Contribution to journalArticle

Pawlik, TM, Ross, MI, Johnson, MM, Schacherer, CW, McClain, DM, Mansfield, PF, Lee, JE, Cormier, JN & Gershenwald, JE 2005, 'Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy', Annals of Surgical Oncology, vol. 12, no. 8, pp. 587-596. https://doi.org/10.1245/ASO.2005.05.025
Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Annals of Surgical Oncology. 2005 Aug;12(8):587-596. https://doi.org/10.1245/ASO.2005.05.025
Pawlik, Timothy M. ; Ross, Merrick I. ; Johnson, Marcella M. ; Schacherer, Christopher W. ; McClain, Dana M. ; Mansfield, Paul F. ; Lee, Jeffrey E. ; Cormier, Janice N. ; Gershenwald, Jeffrey E. / Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. In: Annals of Surgical Oncology. 2005 ; Vol. 12, No. 8. pp. 587-596.
@article{3054c421073140289f6c2a9aee75358e,
title = "Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy",
abstract = "Background: In-transit recurrence is a unique and uncommon pattern of treatment failure in patients with melanoma. Little information exists concerning the incidence, predictors, and natural history of in-transit disease since the introduction of sentinel lymph node biopsy (SLNB). Methods: Between 1991 and 2001, 1395 patients with primary melanoma underwent SLNB. Univariate and multivariate logistic regression analyses were performed to examine the association among known clinicopathologic factors, in-transit recurrence, and distant metastatic failure after the development of in-transit disease. Results: With a median follow-up of 3.9 years, 241 patients (17.3{\%}) experienced disease recurrence, including 91 (6.6{\%}) who developed in-transit recurrence. Independent predictors of in-transit recurrence included age >50 years, a lower extremity location of the primary tumor, Breslow depth, ulceration, and sentinel lymph node (SLN) status. Of the 69 patients who presented with in-transit disease as the sole site of first recurrence, 39 developed distant disease. By univariate analysis, predictors of distant failure among patients with in-transit disease included SLN status, largest metastatic focus in the SLN >2.5 mm2, subcutaneous location of in-transit disease, in-transit tumor size ≥ 2 cm, and a disease-free interval before in-transit recurrence of",
keywords = "In transit, Lymph node, Melanoma, Recurrence, Sentinel lymph node biopsy",
author = "Pawlik, {Timothy M.} and Ross, {Merrick I.} and Johnson, {Marcella M.} and Schacherer, {Christopher W.} and McClain, {Dana M.} and Mansfield, {Paul F.} and Lee, {Jeffrey E.} and Cormier, {Janice N.} and Gershenwald, {Jeffrey E.}",
year = "2005",
month = "8",
doi = "10.1245/ASO.2005.05.025",
language = "English (US)",
volume = "12",
pages = "587--596",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy

AU - Pawlik, Timothy M.

AU - Ross, Merrick I.

AU - Johnson, Marcella M.

AU - Schacherer, Christopher W.

AU - McClain, Dana M.

AU - Mansfield, Paul F.

AU - Lee, Jeffrey E.

AU - Cormier, Janice N.

AU - Gershenwald, Jeffrey E.

PY - 2005/8

Y1 - 2005/8

N2 - Background: In-transit recurrence is a unique and uncommon pattern of treatment failure in patients with melanoma. Little information exists concerning the incidence, predictors, and natural history of in-transit disease since the introduction of sentinel lymph node biopsy (SLNB). Methods: Between 1991 and 2001, 1395 patients with primary melanoma underwent SLNB. Univariate and multivariate logistic regression analyses were performed to examine the association among known clinicopathologic factors, in-transit recurrence, and distant metastatic failure after the development of in-transit disease. Results: With a median follow-up of 3.9 years, 241 patients (17.3%) experienced disease recurrence, including 91 (6.6%) who developed in-transit recurrence. Independent predictors of in-transit recurrence included age >50 years, a lower extremity location of the primary tumor, Breslow depth, ulceration, and sentinel lymph node (SLN) status. Of the 69 patients who presented with in-transit disease as the sole site of first recurrence, 39 developed distant disease. By univariate analysis, predictors of distant failure among patients with in-transit disease included SLN status, largest metastatic focus in the SLN >2.5 mm2, subcutaneous location of in-transit disease, in-transit tumor size ≥ 2 cm, and a disease-free interval before in-transit recurrence of

AB - Background: In-transit recurrence is a unique and uncommon pattern of treatment failure in patients with melanoma. Little information exists concerning the incidence, predictors, and natural history of in-transit disease since the introduction of sentinel lymph node biopsy (SLNB). Methods: Between 1991 and 2001, 1395 patients with primary melanoma underwent SLNB. Univariate and multivariate logistic regression analyses were performed to examine the association among known clinicopathologic factors, in-transit recurrence, and distant metastatic failure after the development of in-transit disease. Results: With a median follow-up of 3.9 years, 241 patients (17.3%) experienced disease recurrence, including 91 (6.6%) who developed in-transit recurrence. Independent predictors of in-transit recurrence included age >50 years, a lower extremity location of the primary tumor, Breslow depth, ulceration, and sentinel lymph node (SLN) status. Of the 69 patients who presented with in-transit disease as the sole site of first recurrence, 39 developed distant disease. By univariate analysis, predictors of distant failure among patients with in-transit disease included SLN status, largest metastatic focus in the SLN >2.5 mm2, subcutaneous location of in-transit disease, in-transit tumor size ≥ 2 cm, and a disease-free interval before in-transit recurrence of

KW - In transit

KW - Lymph node

KW - Melanoma

KW - Recurrence

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=23744460937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744460937&partnerID=8YFLogxK

U2 - 10.1245/ASO.2005.05.025

DO - 10.1245/ASO.2005.05.025

M3 - Article

C2 - 16021533

AN - SCOPUS:23744460937

VL - 12

SP - 587

EP - 596

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -